Abstract
Sleep disorders are one of the most common non-motor symptoms in Parkinson's disease (PD). It can cause a notable decrease in quality of life and functioning in PD patients, as well as place a huge burden on both patients and caregivers. The most cited sleep disorders in PD included insomnia, restless legs syndrome (RLS), rapid eye movement (REM), sleep behavior disorders (RBD), excessive daytime sleepiness (EDS) and sleep disordered breathing (SDB), which can appear alone or several at the same time. In this review, we listed the recommended pharmacological treatments for common sleep disorders in PD, and discussed the recommended dosages, benefits and side effects of relative drugs. We also discussed non-pharmacological treatments to improve sleep quality, including sleep hygiene education, exercise, deep brain stimulation, cognitive behavior therapy and complementary therapies. We tried to find proper interventions for different types of sleep disorders in PD, while minimizing relative side effects.
Keywords: Parkinson's disease, insomnia, restless legs syndrome, RBD, excessive daytime sleepiness, sleep disordered breathing, pharmacological treatments, non-pharmacological treatments.
Graphical Abstract
Current Neuropharmacology
Title:Pharmacological and Non-pharmacological Treatments of Sleep Disorders in Parkinson's Disease
Volume: 19 Issue: 12
Author(s): Reyisha Taximaimaiti, Xingguang Luo and Xiao-Ping Wang*
Affiliation:
- Department of Neurology, Shanghai TongRen Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200336,China
Keywords: Parkinson's disease, insomnia, restless legs syndrome, RBD, excessive daytime sleepiness, sleep disordered breathing, pharmacological treatments, non-pharmacological treatments.
Abstract: Sleep disorders are one of the most common non-motor symptoms in Parkinson's disease (PD). It can cause a notable decrease in quality of life and functioning in PD patients, as well as place a huge burden on both patients and caregivers. The most cited sleep disorders in PD included insomnia, restless legs syndrome (RLS), rapid eye movement (REM), sleep behavior disorders (RBD), excessive daytime sleepiness (EDS) and sleep disordered breathing (SDB), which can appear alone or several at the same time. In this review, we listed the recommended pharmacological treatments for common sleep disorders in PD, and discussed the recommended dosages, benefits and side effects of relative drugs. We also discussed non-pharmacological treatments to improve sleep quality, including sleep hygiene education, exercise, deep brain stimulation, cognitive behavior therapy and complementary therapies. We tried to find proper interventions for different types of sleep disorders in PD, while minimizing relative side effects.
Export Options
About this article
Cite this article as:
Taximaimaiti Reyisha , Luo Xingguang and Wang Xiao-Ping *, Pharmacological and Non-pharmacological Treatments of Sleep Disorders in Parkinson's Disease, Current Neuropharmacology 2021; 19 (12) . https://dx.doi.org/10.2174/1570159X19666210517115706
DOI https://dx.doi.org/10.2174/1570159X19666210517115706 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Functional Activity and Connectivity Differences of Five Resting-State Networks in Patients with Alzheimer’s Disease or Mild Cognitive Impairment
Current Alzheimer Research Current Approaches for Drug Delivery to Central Nervous System
Current Drug Delivery L-Carnosine Modulates Respiratory Burst and Reactive Oxygen Species Production in Neutrophil Biochemistry and Function: May Oral Dosage Form of Non-Hydrolized Dipeptide L-Carnosine Complement Anti-Infective Anti-Influenza Flu Treatment, Prevention and Self-Care as an Alternative to the Conventional Vaccination?
Current Clinical Pharmacology Potential Novel Anxiolytic Drugs
Current Pharmaceutical Design Cerebrolysin and Aquaporin 4 Inhibition Improve Pathological and Motor Recovery after Ischemic Stroke
CNS & Neurological Disorders - Drug Targets Recent Patents in Magnetic Fluid Seals and Applications
Recent Patents on Engineering Raloxifene: Cardiovascular Considerations
Mini-Reviews in Medicinal Chemistry Retinoid-Induced Limb Malformations
Current Pharmaceutical Design Rhinosinusitis in the Pediatric Patient with Cystic Fibrosis
Current Pediatric Reviews Aberrant Splicing, Hyaluronan Synthases and Intracellular Hyaluronan as Drivers of Oncogenesis and Potential Drug Targets
Current Cancer Drug Targets Modulation of Cell Death in Age-Related Diseases
Current Pharmaceutical Design Regulation of Interactions with Sliding Clamps During DNA Replication and Repair
Current Genomics From a Dull Enzyme to Something Else: Facts and Perspectives Regarding Aldose Reductase
Current Medicinal Chemistry The Role of the ATP-Binding Cassette Transporter P-Glycoprotein in the Transport of β-Amyloid Across the Blood-Brain Barrier
Current Pharmaceutical Design Overview and Findings from the Rush Memory and Aging Project
Current Alzheimer Research Somatic Treatments Excluding Psychopharmacology in Obsessive- Compulsive Disorder: A Review.
Reviews on Recent Clinical Trials The Role of Neurogenesis in Neurodegenerative Diseases and its Implications for Therapeutic Development
CNS & Neurological Disorders - Drug Targets Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation Effect of Brain Derived Neurotrophic Factor (BDNF) Gene Variants on Therapeutic Response and the Risk for Schizophrenia
Current Pharmacogenomics Haloperidol Cytotoxicity and Its Relation to Oxidative Stress
Mini-Reviews in Medicinal Chemistry